Oruka Therapeutics Inc. Common Stock vs SYSCO Corporation — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while SYSCO Corporation trades at $81.5 (market cap $38.88B). The key difference: SYSCO Corporation is far larger — about 7.5× Oruka Therapeutics Inc. Common Stock's market cap, and SYSCO Corporation pays a 2.78% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and SYSCO Corporation for 78 Days on average.
| ORKA | SYY | |
|---|---|---|
Market Cap | $5.18B | $38.88B |
Volume | 490,798 | 2,477,462 |
Sector | Health | Consumer Staples |
52-Week High | $113.08 | $91.16 |
52-Week Low | $26.19 | $69.30 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $4.31B | $52.06B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SYY trades at $80.97, up 2.88% with a bearish technical signal despite recent earnings beats. The company maintains steady revenue growth, reaching $81.37B in 2025, with strong profitability metrics including 78.16% ROE. Recent developments include a $500M AI efficiency program and a $1.5B senior notes offering. Analyst consensus remains positive with 60% buy ratings and an $85.75 price target, though technical indicators show resistance near $79-80 levels.
SYY presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 0.45 P/S ratio and dividend yield, supported by consistent revenue growth and AI-driven efficiency initiatives. Key risks include high debt levels at 49.75% debt-to-asset ratio and margin pressure as net income margin declined to 2.08%. Institutional ownership trends positive with recent pension fund increases.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →